BioSpace News Archive

Pharm Country

HUTCHMED Highlights First Presentation of Results of the SAVANNAH Global Phase II Trial of Savolitinib plus TAGRISSO® at the 2022 WCLC Annual Meeting— 49% ORR amongst SAVANNAH patients with higher MET levels —

HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces the first presentation of results from the ongoing SAVANNAH global Phase II trial at the upcoming International Association for the Study of Lung Cancer (IASLC) 2022 World Conference on Lung Cancer (“WCLC”), taking place August 6-9 in Vienna, Austria.

July 12, 2022
·
20 min read
Business

Aculys Pharma and SUSMED Have Entered into a Contract to Conduct the World’s First Clinical Trial Utilizing Blockchain Technology

Aculys Pharma, Inc. (“Aculys Pharma” Headquarters: Minato-ku, Tokyo, President and CEO: Kazunari Tsunaba), has entered into a contract with SUSMED, Inc., a company that promotes digital medicine, (“SUSMED” Headquarters: Chuo-ku, Tokyo, CEO: Taro Ueno) to conduct the world’s first1 corporate-sponsored clinical trial using blockchain technology.

July 12, 2022
·
8 min read